Read on Twitter
Cool innovation in cancer screening: liquid biopsy
Signals (methylation status) from blood samples + DNA sequencing
https://www.wsj.com/articles/cancer-screening-leaps-forward-11593973586
$ILMN $GH #Grail
Signals (methylation status) from blood samples + DNA sequencing
https://www.wsj.com/articles/cancer-screening-leaps-forward-11593973586
$ILMN $GH #Grail
ARK on DNA methylation: similar to bold-facing certain letters of the genome
Benefit is that requires less sequencing but surfaces more info
https://twitter.com/sbarnettARK/status/1280214868461789186?s=20
$GRAL $GH
Benefit is that requires less sequencing but surfaces more info
https://twitter.com/sbarnettARK/status/1280214868461789186?s=20
$GRAL $GH
Liquid biopsy entering mainstream USA Today news
Benefits: 1) multiple tests to track tumor changes / residual disease after surgery; 2) convenience; 3) find clinical trials for patients w/ advanced cancer; 4) potential for earlier detection
https://www.usatoday.com/story/news/health/2020/09/03/cancer-fda-approves-liquid-biopsy-tests-can-improve-treatment/5644829002/
$GH $GRAL
Benefits: 1) multiple tests to track tumor changes / residual disease after surgery; 2) convenience; 3) find clinical trials for patients w/ advanced cancer; 4) potential for earlier detection
https://www.usatoday.com/story/news/health/2020/09/03/cancer-fda-approves-liquid-biopsy-tests-can-improve-treatment/5644829002/
$GH $GRAL
Grail $GRAL filing to go public
Timeline: launch its blood test to detect cancer - Galleri- as a laboratory developed test in 2021+ seek FDA approval in 2023 https://twitter.com/matthewherper/status/1303659723523321857?s=20
Timeline: launch its blood test to detect cancer - Galleri- as a laboratory developed test in 2021+ seek FDA approval in 2023 https://twitter.com/matthewherper/status/1303659723523321857?s=20
Good thread on pros / cons on $ILMN re-acquiring $GRAL
Summary: Good asset, but building infrastructure of a oncology diagnostic co is not easy + some R&D risk + more complicated investor narrative
https://twitter.com/sbarnettARK/status/1308096536962904064?s=20
#liquidbiopsy
Summary: Good asset, but building infrastructure of a oncology diagnostic co is not easy + some R&D risk + more complicated investor narrative
https://twitter.com/sbarnettARK/status/1308096536962904064?s=20
#liquidbiopsy
